Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

9 avril 2021 mis à jour par: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)

This study will be looking at what dose of tremelimumab and olaparib is safe and effective in patients with persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma).

Aperçu de l'étude

Statut

Résilié

Les conditions

Intervention / Traitement

Description détaillée

This clinical trial was initially intended to be a Phase 1/2 trial, but the trial never moved forward to Phase 2 prior to termination.

Type d'étude

Interventionnel

Inscription (Réel)

24

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • Maryland
      • Baltimore, Maryland, États-Unis, 21231
        • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Signed informed consent form
  2. Age ≥ 18 years
  3. Recurrent or persistent EOC (epithelial ovarian, fallopian tube or primary peritoneal carcinoma)
  4. Have archival tissue or willingness to undergo a tumor biopsy
  5. Have measurable disease
  6. Have had one prior taxane-platinum-based chemotherapeutic regimen
  7. Have had a treatment-free interval following platinum-based therapy of less than 12 months, have progressed during platinum-based therapy, or had persistent disease after a platinum-based regimen
  8. Have received hormonal therapy
  9. ECOG Performance Status of 0 to 1
  10. Ability to take oral medications
  11. HIV, HTLV-1, HBV, and HCV negative
  12. Adequate organ and bone marrow function as defined by study-specified laboratory tests
  13. Normal blood coagulation parameters
  14. Life expectancy greater than 16 weeks
  15. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
  16. Willing and able to comply with study procedures

Exclusion Criteria:

  1. Prior therapy with an anti-CTLA-4 antibody or PARP inhibitor
  2. Active infection requiring antibiotics
  3. Active autoimmune disease
  4. Active and uncontrolled intercurrent illness
  5. History of other cancers within the past 5 years
  6. Systemically active steroid use
  7. Receiving systemic chemotherapy or radiotherapy within 4 weeks prior to the first dose of study drug
  8. Use of ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir
  9. Requirement for chronic parenteral hydration/nutrition
  10. Vaccination with live attenuated vaccine within 1 month prior to first dose of study drug
  11. Patients with untreated brain metastases, treated brain metastases that are not stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy
  12. Patients with myelodysplastic syndrome/acute myeloid leukaemia
  13. History of diverticulitis
  14. History of bleeding disorder or diathesis.
  15. Serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw
  16. Major surgical procedure within 28 days of study enrollment, or anticipated while on study.
  17. Pregnant or breast feeding woman

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm A: Tremelimumab Alone
25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
Médicament: Tremelimumab
Expérimental: Arm B1: DESE Tremelimumab and Olaparib
18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
Médicament: Tremelimumab
Médicament: Olaparib
Autres noms:
  • LYNPARZA
Expérimental: Arm B2: Tremelimumab and Olaparib
25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
Médicament: Tremelimumab
Médicament: Olaparib
Autres noms:
  • LYNPARZA

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Adverse events as a measure of the safety and tolerability profile of tremelimumab in combination with olaparib
Délai: 4 years
Number of participants experiencing study drug-related dose limiting toxicities (DLTs). Dose escalation (phase I) portion of the trial only.
4 years
Fold change from baseline in the ratio of peripheral CD4+ICOShi T cells and Regulatory T cells
Délai: 4 years
Dose escalation (phase I) portion of the trial only.
4 years
Maximum Tolerated Dose (MTD) of tremelimumab combined with olaparib
Délai: 4 years
Dose escalation (phase I) portion of the trial only.
4 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Survie globale (OS)
Délai: 4 années
La SG sera mesurée à partir de la date de la première dose jusqu'au décès ou à la fin du suivi (la SG sera censurée à la date à laquelle le sujet a été connu pour la dernière fois en vie pour les sujets sans documentation de décès au moment de l'analyse). Estimation basée sur la courbe de Kaplan-Meier.
4 années
Progression Free Survival (PFS) Rate at 6 months by RECIST
Délai: 6 months
PFS rate is defined as the percentage of patients with disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria) or death due to any cause at 6 months. Per RECIST 1.1 criteria, Complete Response (CR) = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.
6 months
Progression Free Survival (PFS) Rate at 6 months by irRECIST
Délai: 6 months
PFS rate is defined as the percentage of patients with disease progression (irPD or relapse from irCR as assessed using irRECIST criteria) or death due to any cause at 6 months. Per irRECIST criteria, irCR = disappearance of all lesions, irPR is =>30% decrease in tumor burden, irPD is >20% increase in tumor burden compared with nadir, irSD is <30% decrease in tumor burden compared with baseline cannot be established nor <20% increase compared with nadir. Estimation based on the Kaplan-Meier curve.
6 months
Objective Response Rate (ORR) by RECIST
Délai: 4 years
Objective Response Rate (ORR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. Per RECIST 1.1 criteria, CR = disappearance of all target lesions and PR is =>30% decrease in sum of diameters of target lesions.
4 years
Objective Response Rate (ORR) by irRECIST
Délai: 4 years
Objective Response Rate (irORR) is defined as the percentage of patients achieving a complete response (irCR) or partial response (irPR) based on irRECIST criteria. Per irRECIST criteria, irCR = disappearance of all lesions and irPR is =>30% decrease in tumor burden.
4 years
Duration of Response by RECIST
Délai: 4 years
Number of months from the start date of PR or CR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, PR is =>30% decrease in sum of diameters of target lesions, and PD is >20% increase in sum of diameters of target lesions.
4 years
Duration of Response by irRECIST
Délai: 4 years
Number of months from the start date of irPR or irCR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented. Per irRECIST criteria, irCR = disappearance of all lesions, irPR is =>30% decrease in tumor burden, and irPD is is >20% increase in tumor burden compared with nadir.
4 years
Disease Control Rate (DCR)
Délai: 4 years
DCR is defined as the number of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria at any time during the study. CR = disappearance of all target lesions, PR is =>30% decrease in sum of diameters of target lesions, PD is >20% increase in sum of diameters of target lesions, SD is <30% decrease or <20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.
4 years
Progression-Free Survival (PFS)
Délai: 4 years
PFS is defined as the number of patients with disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.
4 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborateurs

AstraZeneca
MedImmune LLC

Les enquêteurs

  • Chercheur principal: Stéphanie Gaillard, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

8 janvier 2016

Achèvement primaire (Réel)

5 mars 2020

Achèvement de l'étude (Réel)

5 mars 2020

Dates d'inscription aux études

Première soumission

26 juin 2015

Première soumission répondant aux critères de contrôle qualité

29 juin 2015

Première publication (Estimation)

30 juin 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 avril 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 avril 2021

Dernière vérification

1 avril 2021

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • J15113
  • IRB00064379 (Autre identifiant: JHM IRB)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Carcinome péritonéal primaire

Essais cliniques sur Tremelimumab

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Togo

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

S'abonner